ALGS
HEALTHCAREAligos Therapeutics Inc
$6.37+0.02 (+0.31%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ALGS Today?
No stock-specific AI insight has been generated for ALGS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.47$13.69
$6.37
Fundamentals
Market Cap$39M
P/E Ratio—
EPS$-2.45
Dividend Yield—
Dividend / Share—
ROE-2.0%
Profit Margin—
Debt / Equity—
Trading
Volume151K
Avg Volume (10D)—
Shares Outstanding5.4M
ALGS News
21 articles- Aligos lands FDA Fast Track and a $25M China deal for HBV drugStock Titan·May 7, 2026
- Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial ResultsThe Manila Times·May 7, 2026
- Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 30, 2026
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 24, 2026
- Aligos and Xiamen Amoytop sign deal for HBV therapyPharmaceutical-technology·Apr 17, 2026
- Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus InfectionGlobeNewswire Inc.·Apr 16, 2026
- Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track DesignationYahoo Finance·Apr 14, 2026
- Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 5, 2026
- Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026Yahoo Finance·Feb 26, 2026
- Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)Yahoo Finance·Feb 23, 2026
- Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress UpdatesYahoo Finance·Jan 21, 2026
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial OfficerYahoo Finance·Jan 13, 2026
- Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R TherapeuticsYahoo Finance·Jan 8, 2026
- Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash WiselyYahoo Finance·Jan 7, 2026
- Aligos Therapeutics Presents Positive Data at HEP-DART 2025Yahoo Finance·Dec 11, 2025
- Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025Yahoo Finance·Nov 10, 2025
- Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial ResultsYahoo Finance·Nov 6, 2025
- Aligos Therapeutics to Present at Upcoming Investor ConferencesYahoo Finance·Nov 4, 2025
- Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025Yahoo Finance·Oct 30, 2025
- Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184Yahoo Finance·Oct 16, 2025
- Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease ConferenceYahoo Finance·Oct 14, 2025
All 21 articles loaded
Price Data
Open$6.31
Previous Close$6.35
Day High$6.64
Day Low$6.24
52 Week High$13.69
52 Week Low$4.47
52-Week Range
$4.47$13.69
$6.37
Fundamentals
Market Cap$39M
P/E Ratio—
EPS$-2.45
Dividend Yield—
Dividend / Share—
ROE-2.0%
Profit Margin—
Debt / Equity—
Trading
Volume151K
Avg Volume (10D)—
Shares Outstanding5.4M
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—